IBAB Stock Overview
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally.
Ion Beam Applications Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€15.80|
|52 Week High||€20.45|
|52 Week Low||€13.62|
|1 Month Change||-1.74%|
|3 Month Change||-11.73%|
|1 Year Change||-7.39%|
|3 Year Change||6.97%|
|5 Year Change||-69.40%|
|Change since IPO||-69.29%|
Recent News & Updates
Ion Beam Applications (EBR:IBAB) Is Investing Its Capital With Increasing Efficiency
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
|IBAB||BE Medical Equipment||BE Market|
Return vs Industry: IBAB exceeded the Belgian Medical Equipment industry which returned -13.2% over the past year.
Return vs Market: IBAB underperformed the Belgian Market which returned -4.5% over the past year.
|IBAB Average Weekly Movement||4.5%|
|Medical Equipment Industry Average Movement||7.4%|
|Market Average Movement||5.1%|
|10% most volatile stocks in BE Market||7.9%|
|10% least volatile stocks in BE Market||3.2%|
Stable Share Price: IBAB is not significantly more volatile than the rest of Belgian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: IBAB's weekly volatility (4%) has been stable over the past year.
About the Company
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems.
Ion Beam Applications Fundamentals Summary
|IBAB fundamental statistics|
Is IBAB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IBAB income statement (TTM)|
|Cost of Revenue||€205.27m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 31, 2022
|Earnings per share (EPS)||0.13|
|Net Profit Margin||1.24%|
How did IBAB perform over the long term?See historical performance and comparison
1.2%Current Dividend Yield
Is Ion Beam Applications undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IBAB (€15.8) is trading below our estimate of fair value (€44.94)
Significantly Below Fair Value: IBAB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IBAB is poor value based on its PE Ratio (119.9x) compared to the European Medical Equipment industry average (31x).
PE vs Market: IBAB is poor value based on its PE Ratio (119.9x) compared to the Belgian market (11.8x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IBAB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IBAB is overvalued based on its PB Ratio (3.7x) compared to the XE Medical Equipment industry average (3.2x).
How is Ion Beam Applications forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if IBAB's forecast earnings growth is above the savings rate (1.1%).
Earnings vs Market: Insufficient data to determine if IBAB's earnings are forecast to grow faster than the Belgian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: IBAB's revenue (13.8% per year) is forecast to grow faster than the Belgian market (0.9% per year).
High Growth Revenue: IBAB's revenue (13.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IBAB's Return on Equity is forecast to be high in 3 years time
How has Ion Beam Applications performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IBAB has high quality earnings.
Growing Profit Margin: IBAB's current net profit margins (1.2%) are lower than last year (10.2%).
Past Earnings Growth Analysis
Earnings Trend: IBAB's earnings have grown significantly by 39.9% per year over the past 5 years.
Accelerating Growth: IBAB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IBAB had negative earnings growth (-87.8%) over the past year, making it difficult to compare to the Medical Equipment industry average (22.5%).
Return on Equity
High ROE: IBAB's Return on Equity (3.1%) is considered low.
How is Ion Beam Applications's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: IBAB's short term assets (€427.2M) exceed its short term liabilities (€348.6M).
Long Term Liabilities: IBAB's short term assets (€427.2M) exceed its long term liabilities (€71.6M).
Debt to Equity History and Analysis
Debt Level: IBAB has more cash than its total debt.
Reducing Debt: IBAB's debt to equity ratio has increased from 19.8% to 31.5% over the past 5 years.
Debt Coverage: IBAB's debt is well covered by operating cash flow (219.8%).
Interest Coverage: IBAB's interest payments on its debt are well covered by EBIT (6.7x coverage).
What is Ion Beam Applications's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: IBAB's dividend (1.2%) isn’t notable compared to the bottom 25% of dividend payers in the Belgian market (1.77%).
High Dividend: IBAB's dividend (1.2%) is low compared to the top 25% of dividend payers in the Belgian market (5.82%).
Stability and Growth of Payments
Stable Dividend: IBAB has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: IBAB's dividend payments have increased, but the company has only paid a dividend for 7 years.
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (144.1%), IBAB's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (6.8%), IBAB's dividend payments are thoroughly covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Olivier Legrain (53 yo)
Mr. Olivier Legrain has been the Chief Executive Officer, President and Executive Director at Ion Beam Applications, S.A. since May 9, 2012 and served as its President of Molecular Medicine at Ion Beam App...
CEO Compensation Analysis
Compensation vs Market: Olivier's total compensation ($USD933.63K) is about average for companies of similar size in the Belgian market ($USD736.05K).
Compensation vs Earnings: Olivier's compensation has been consistent with company performance over the past year.
Experienced Management: IBAB's management team is seasoned and experienced (10 years average tenure).
Experienced Board: IBAB's board of directors are considered experienced (8.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ion Beam Applications SA's employee growth, exchange listings and data sources
- Name: Ion Beam Applications SA
- Ticker: IBAB
- Exchange: ENXTBR
- Founded: 1986
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €465.183m
- Shares outstanding: 29.44m
- Website: https://www.iba-worldwide.com
Number of Employees
- Ion Beam Applications SA
- 3, Chemin du Cyclotron
- Walloon Brabant
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/22 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.